AstraZeneca

AstraZeneca enters agreement with Recordati for Seloken in Europe

22 Maj 2017 08:02

AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK

AstraZeneca to present scientific advancements from growing respiratory portfolio at the American Thoracic Society conference 2017

18 Maj 2017 08:05

AstraZeneca and its global biologics research and development arm, MedImmune, will present new data from its growing respiratory portfolio and pipeline at the 113th annual conference of the American Thoracic Society (ATS) in Washington, DC, USA, 19-24 May 2017

Stipendium till Katalin Dobra

12 Maj 2017 12:09

Idag tilldelas Universitetslektor Katalin Dobra, verksam vid Karolinska Institutet och Överläkare vid Karolinska Universitetssjukhuset, Svensk Förening för Patologis (SvFP), stipendie för 2017. Stipendiet uppmärksammar personer som bidrar med betydande insatser inom molekylärpatologisk diagnostik och har instiftats av Svensk Förening för Patologi (SvFP) och AstraZeneca.

Imfinzi significantly reduces the risk of disease worsening or death in the phase III pacific trial for stage III unresectable lung cancer

12 Maj 2017 08:05

Imfinzi met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer in a planned interim analysis

AstraZeneca provides update on STRATOS 1 phase III trial of tralokinumab in severe, uncontrolled asthma

10 Maj 2017 08:04

Tralokinumab did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate
Second pivotal Phase III trial STRATOS 2 is ongoing with results expected in second half of 2017
AstraZenecaand MedImmune, its global biologics research and development arm, today announced that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet i

Lungcancerstipendium till Dr Mikael Johansson

5 Maj 2017 18:39

Idag tilldelas Överläkare Mikael Johansson, verksam vid Cancercentrum, Norrlands Universitetssjukhus, SLUSG-stipendiet 2017. Stipendiet har instiftats av Svenska Lungcancerstudiegruppen (SLUSG) och AstraZeneca och uppmärksammar personer som bidrar med betydande insatser inom lungcancerområdet.

AstraZeneca PLC:s resultatrapport för första kvartalet 2017

27 April 2017 08:03

En positiv start med fortsatt nyhetsflöde kring vår forskningsportfölj i det som har potential att bli ett avgörande år för bolaget

Tagrisso receives full approval in the EU

25 April 2017 14:34

Full approval follows Tagrisso’s expedited Conditional Marketing Authorisation as first-in-class medicine for patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer

Tagrisso (osimertinib) receives US FDA full approval

31 Mars 2017 08:04

Conversion from accelerated to full approval confirms the potential of Tagrissoto become standard of care in the US Approval based on Phase III AURA3 trial thatdemonstrated significant improvement in progression-free survival with Tagrisso as compared to chemotherapy

AstraZeneca’s potential medicine for Neuromyelitis Optica Spectrum Disorder receives orphan designation in Europe

29 Mars 2017 08:04

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Medicines Agency (EMA) has granted orphan designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

AstraZeneca to share its robust early science in Oncology with the medical community at AACR 2017

28 Mars 2017 08:03

60 abstracts from early oncology portfolio including 7 oral presentations, across Tumour Drivers and Resistance, Immuno-Oncology, Antibody-Drug Conjugates and DNA Damage Response Potential new medicines targeting cancer cell-death mechanisms highlight potential of emerging Tumour Drivers and Resistance research

Tagrisso approved in China as first-in-class treatment for EGFR T790M mutation-positive metastatic non-small cell lung cancer

27 Mars 2017 13:11

First AstraZeneca medicine approved under China’s new Priority Review pathway Tagrisso is an important new medicine in a country where lung cancer is the leading cause of cancer-related deaths and EGFR-mutation rates are among highest globally

AstraZenecas observationsstudie CVD-REAL visar att SGLT-2-hämmare signifikant minskade antalet sjukhusinläggningar på grund av hjärtsvikt och antalet dödsfall jämfört med andra läkemedel vid diabetes typ 2

21 Mars 2017 15:26

Banbrytande data från en internationell observationsstudie av över 300 000 patienter med typ-2 diabetes visar att behandling med SGLT-2-hämmare minskade risken för sjukhusinläggning på grund av hjärtsvikt med 39% och den totala mortaliteten med 51%.

AstraZeneca and Circassia enter strategic collaboration in respiratory disease

17 Mars 2017 08:07

Circassia will lead promotion of Tudorza and prepare for potential launch of Duaklir in the US Strategic collaboration further sharpens AstraZeneca’s respiratory focus on Symbicort, Bevespi Aerosphere, benralizumab and other development programmes

AstraZeneca receives Complete Response Letter from US FDA for ZS-9 (sodium zirconium cyclosilicate) for hyperkalaemia

17 Mars 2017 08:04

AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ZS-9 (sodium zirconium cyclosilicate).

Fas III-studien SOLO-2 visar på förlängd progressionsfri överlevnad med Lynparza som underhållsbehandling av BRCA-muterad äggstockscancer

14 Mars 2017 19:32

Lynparza minskade risken för sjukdomsprogression med 70 %, med en prövarbedömd progressionsfri överlevnad på 19,1 månader, jämfört med 5,5 månader för placebo En blindad, oberoende central granskning visade en progressionsfri överlevnad på 30,2 månader, jämfört med 5,5 månader för placebo

Medimmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897

3 Mars 2017 08:05

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, today announced an agreement to develop and commercialise MEDI8897 jointly.